Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has recently published a study that showcases the potential of its TURBO-ZM platform to target the human ribosome for therapeutic purposes. The study, titled "A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer,"..